DOCSLIB.ORG

PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE 77337-76-9 ACOTIAMIDUM 185106-16-5 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7 ACRIFLAVINIUM CHLORIDE 8063-24-9 ACEBUTOLOL 37517-30-9 ACRIHELLIN 67696-82-6 ACECAINIDE 32795-44-1 ACRISORCIN 7527-91-5 ACECARBROMAL 77-66-7 ACRIVASTINE 87848-99-5 ACECLIDINE 827-61-2 ACROCINONIDE 28971-58-6 ACECLOFENAC 89796-99-6 ACRONINE 7008-42-6 ACEDAPSONE 77-46-3 ACTAGARDIN ACEDIASULFONE SODIUM 127-60-6 ACTAPLANIN 37305-75-2 ACEDOBEN 556-08-1 ACTARIT 18699-02-0 ACEFLURANOL 80595-73-9 ACTINOQUINOL 15301-40-3 ACEFURTIAMINE 10072-48-7 ACTISOMIDE 96914-39-5 ACEFYLLINE CLOFIBROL 70788-27-1 ACTODIGIN 36983-69-4 ACEFYLLINE PIPERAZINE 18428-63-2 ADAFENOXATE 82168-26-1 ACEGLATONE 642-83-1 ADALIMUMABUM 331731-18-1 ACEGLUTAMIDE 2490-97-3 ADAMEXINE 54785-02-3 ACEMANNAN 110042-95-0 ADAPALENE 106685-40-9 ACEMETACIN 53164-05-9 ADAPROLOL 101479-70-3 ACENEURAMIC ACID 131-48-6 ADARGILEUKINUM ALFA 250710-65-7 ACENOCOUMAROL 152-72-7 ADATANSERIN 127266-56-2 ACEPERONE 807-31-8 ADECATUMUMABUM 503605-66-1 ACEPROMAZINE 61-00-7 ADEFOVIR 106941-25-7 ACEPROMETAZINE 13461-01-3 ADEKALANTUM 227940-00-3 ACEQUINOLINE 42465-20-3 ADELMIDROL 1675-66-7 ACESULFAME 33665-90-6 ADEMETIONINE 17176-17-9 ACETAMINOSALOL 118-57-0 ADENOSINE PHOSPHATE 61-19-8 ACETARSOL 97-44-9 ADIBENDAN 100510-33-6 ACETAZOLAMIDE 59-66-5 ADICILLIN 525-94-0 ACETERGAMINE 3031-48-9 ADIMOLOL 78459-19-5 ACETIAMINE 299-89-8 ADINAZOLAM 37115-32-5 ACETIROMATE 2260-08-4 ADIPHENINE 64-95-9 ACETOHEXAMIDE 968-81-0 ADIPIODONE 606-17-7 ACETOHYDROXAMIC ACID 546-88-3 ADITEREN 56066-19-4 ACETOPHENAZINE 2751-68-0 ADITOPRIM 56066-63-8 ACETORPHINE 25333-77-1 ADOSOPINE 88124-26-9 ACETRYPTINE 3551-18-6 ADOZELESIN 110314-48-2 ACETYLCHOLINE CHLORIDE 60-31-1 ADRAFINIL 63547-13-7 ACETYLCYSTEINE 616-91-1 ADRENALONE 99-45-6 ACETYLDIGITOXIN 1111-39-3 ADROGOLIDUM 171752-56-0 ACETYLLEUCINE 99-15-0 AFALANINE 2901-75-9 ACETYLMETHADOL 509-74-0 AFELETECANUM 215604-75-4 ACEVALTRATE 25161-41-5 AFELIMOMAB 156227-98-4 ACEXAMIC ACID 57-08-9 AFLOQUALONE 56287-74-2 ACICLOVIR 59277-89-3 AFOVIRSEN 151356-08-0 ACIDUM ARUNDICUM 185517-21-9 AFUROLOL 65776-67-2 ACIDUM CALOXETICUM 135306-78-4 AGALSIDASUM ALFA 104138-64-9 ACIDUM CARGLUMICUM 1188-38-1 AGALSIDASUM BETA 104138-64-9 AGANODINE 86696-87-9 ALMOXATONE 84145-89-1 AGLEPRISTONE 124478-60-0 ALMURTIDE 61136-12-7 AGOMELATINE 138112-76-2 ALNESPIRONE 138298-79-0 AKLOMIDE 3011-89-0 ALNIDITAN 152317-89-0 ALACEPRIL 74258-86-9 ALONACIC 105292-70-4 ALAFOSFALIN 60668-24-8 ALONIMID 2897-83-8 ALAGEBRIUM CHLORIDUM 341028-37-3 ALORACETAM 119610-26-3 ALAMIFOVIRUM 193681-12-8 ALOSETRON 122852-42-0 ALANINE 56-41-7 ALOVUDINE 25526-93-6 ALANOSINE 5854-93-3 ALOXIPRIN 9014-67-9 ALAPROCLATE 60719-82-6 ALOXISTATIN 88321-09-9 ALATROFLOXACIN 157182-32-6 ALOZAFONE 65899-72-1 ALAZANINE TRICLOFENATE 5779-59-9 ALPERTINE 27076-46-6 ALBACONAZOLUM 187949-02-6 ALPHACETYLMETHADOL 17199-58-5 ALBENDAZOLE 54965-21-8 ALPHAMEPRODINE 468-51-9 ALBENDAZOLE OXIDE 54029-12-8 ALPHAMETHADOL 17199-54-1 ALBIFYLLINE 107767-55-5 ALPHAPRODINE 77-20-3 ALBUTOIN 830-89-7 ALPIDEM 82626-01-5 ALCLOFENAC 22131-79-9 ALPIROPRIDE 81982-32-3 ALCLOMETASONE 67452-97-5 ALPRAFENONE 124316-02-5 ALCLOXA 1317-25-5 ALPRAZOLAM 28981-97-7 ALCURONIUM CHLORIDE 15180-03-7 ALPRENOLOL 13655-52-2 ALDESULFONE SODIUM 144-75-2 ALPROSTADIL 745-65-3 ALDIOXA 5579-81-7 ALRESTATIN 51411-04-2 ALDOSTERONE 52-39-1 ALSACTIDE 34765-96-3 ALEFACEPTUM 222535-22-0 ALTANSERIN 76330-71-7 ALEMCINALUM 150785-53-8 ALTAPIZONE 93277-96-4 ALEMTUZUMABUM 216503-57-0 ALTECONAZOLE 93479-96-0 ALENDRONIC ACID 66376-36-1 ALTEPLASE 105857-23-6 ALENTEMOL 112891-97-1 ALTINICLINUM 179120-92-4 ALEPRIDE 66564-15-6 ALTIZIDE 5588-16-9 ALESTRAMUSTINE 139402-18-9 ALTOQUALINE 121029-11-6 ALEXIDINE 22573-93-9 ALTRENOGEST 850-52-2 ALEXITOL SODIUM 66813-51-2 ALTRETAMINE 645-05-6 ALFACALCIDOL 41294-56-8 ALTUMOMAB 156586-92-4 ALFADEX 10016-20-3 ALUMINIUM CLOFIBRATE 24818-79-9 ALFADOLONE 14107-37-0 ALUSULF 61115-28-4 ALFAPROSTOL 74176-31-1 ALVAMELINUM 120241-31-8 ALFATRADIOLUM 57-91-0 ALVERINE 150-59-4 ALFAXALONE 23930-19-0 ALVIMOPANUM 156053-89-3 ALFENTANIL 71195-58-9 ALVIRCEPT SUDOTOX 137487-62-8 ALFETAMINE 4255-23-6 ALVOCIDIBUM 146426-40-6 ALFIMEPRASUM 259074-76-5 AMADINONE 30781-27-2 ALFUZOSIN 81403-80-7 AMAFOLONE 50588-47-1 ALGELDRATE 1330-44-5 AMANOZINE 537-17-7 ALGESTONE 595-77-7 AMANTADINE 768-94-5 ALGLUCERASE 143003-46-7 AMANTANIUM BROMIDE 58158-77-3 ALGLUCOSIDASUM ALFA 420784-05-0 AMANTOCILLIN 10004-67-8 ALIBENDOL 26750-81-2 AMBAMUSTINE 85754-59-2 ALICAFORSENUM 185229-68-9 AMBASILIDE 83991-25-7 ALICONAZOLE 63824-12-4 AMBAZONE 539-21-9 ALIFEDRINE 78756-61-3 AMBENONIUM CHLORIDE 115-79-7 ALIFLURANE 56689-41-9 AMBENOXAN 2455-84-7 ALILUSEMUM 144506-11-6 AMBICROMIL 58805-38-2 ALIMADOL 52742-40-2 AMBOMYCIN 1402-81-9 ALIMEMAZINE 84-96-8 AMBRISENTANUM 177036-94-1 ALINASTINE 154541-72-7 AMBROXOL 18683-91-5 ALINIDINE 33178-86-8 AMBRUTICIN 58857-02-6 ALIPAMIDE 3184-59-6 AMBUCAINE 119-29-9 ALISKIRENUM 173334-57-1 AMBUCETAMIDE 519-88-0 ALITRETINOINUM 5300-03-8 AMBUSIDE 3754-19-6 ALIZAPRIDE 59338-93-1 AMCINAFAL 3924-70-7 ALLETORPHINE 23758-80-7 AMCINAFIDE 7332-27-6 ALLOBARBITAL 52-43-7 AMCINONIDE 51022-69-6 ALLOCLAMIDE 5486-77-1 AMDOXOVIRUM 145514-04-1 ALLOCUPREIDE SODIUM 5965-40-2 AMEBUCORT 83625-35-8 ALLOMETHADIONE 526-35-2 AMEDALIN 22136-26-1 ALLOPURINOL 315-30-0 AMEDIPLASUM 151912-11-7 ALLYLESTRENOL 432-60-0 AMELOMETASONE 123013-22-9 ALLYLPRODINE 25384-17-2 AMELTOLIDE 787-93-9 ALLYLTHIOUREA 109-57-9 AMELUBANTUM 346735-24-8 ALMADRATE SULFATE 60239-66-9 AMESERGIDE 121588-75-8 ALMAGATE 66827-12-1 AMETANTRONE 64862-96-0 ALMAGODRATE AMEZEPINE 60575-32-8 ALMASILATE 71205-22-6 AMEZINIUM METILSULFATE 30578-37-1 ALMECILLIN 87-09-2 AMFEBUTAMONE 34911-55-2 ALMESTRONE 10448-96-1 AMFECLORAL 5581-35-1 ALMINOPROFEN 39718-89-3 AMFENAC 51579-82-9 ALMITRINE 27469-53-0 AMFEPENTOREX 15686-27-8 ALMOKALANT 123955-10-2 AMFEPRAMONE 90-84-6 ALMOTRIPTAN 154323-57-6 AMFETAMINE 300-62-9 Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 AMFETAMINIL 17590-01-1 AMPICILLIN 69-53-4 AMFLUTIZOLE 82114-19-0 AMPIROXICAM 99464-64-9 AMFOMYCIN 1402-82-0 AMPRENAVIRUM 161814-49-9 AMFONELIC ACID 15180-02-6 AMPROLIUM 121-25-5 AMICARBALIDE 3459-96-9 AMPYRIMINE 5587-93-9 AMICIBONE 23271-63-8 AMPYZINE 5214-29-9 AMICYCLINE 5874-95-3 AMQUINATE 17230-85-2 AMIDANTEL 49745-00-8 AMRINONE 60719-84-8 AMIDAPSONE 3569-77-5 AMRUBICIN 110267-81-7 AMIDEFRINE MESILATE 1421-68-7 AMSACRINE 51264-14-3 AMIFLAMINE 77518-07-1 AMTOLMETIN GUACIL 87344-06-7 AMIFLOVERINE 54063-24-0 AMYLMETACRESOL 1300-94-3 AMIFLOXACIN 86393-37-5 ANAGESTONE 2740-52-5 AMIFOSTINE 20537-88-6 ANAGRELIDE 68475-42-3 AMIGLUMIDUM 119363-62-1 ANAKINRA 143090-92-0 AMIKACIN 37517-28-5 ANARITIDE 95896-08-5 AMIKHELLINE 4439-67-2 ANASTROZOLE 120511-73-1 AMILORIDE 2609-46-3 ANATIBANTUM 209733-45-9 AMINDOCATE 31386-24-0 ANATUMOMABUM MAFENATOXUM (NONE) AMINEPTINE 57574-09-1 ANAXIRONE 77658-97-0 AMINITROZOLE 140-40-9 ANAZOCINE 15378-99-1 AMINOACRIDINE 90-45-9 ANAZOLENE SODIUM 3861-73-2 AMINOCAPROIC ACID 60-32-2 ANCAROLOL 75748-50-4 AMINOETHYL NITRATE 646-02-6 ANCESTIMUM 163545-26-4 AMINOGLUTETHIMIDE 125-84-8 ANCITABINE 31698-14-3 AMINOMETRADINE 642-44-4 ANCRIVIROCUM 370893-06-4 AMINOPHENAZONE 58-15-1 ANCROD 9046-56-4 AMINOPHENAZONE CYCLAMATE 747-30-8 ANDOLAST 132640-22-3 AMINOPHYLLINE 317-34-0 ANDROSTANOLONE 521-18-6 AMINOPROMAZINE 58-37-7 ANECORTAVUM 7753-60-8 AMINOPTERIN SODIUM 58602-66-7 ANGIOTENSIN II 4474-91-3 AMINOQUINOL 10023-54-8 ANGIOTENSINAMIDE 53-73-6 AMINOQUINURIDE 3811-56-1 ANIDOXIME 34297-34-2 AMINOREX 2207-50-3 ANIDULAFUNGINUM 166663-25-8 AMINOTHIAZOLE 96-50-4 ANILAMATE 5591-49-1 AMINOXYTRIPHENE 5585-64-8 ANILERIDINE 144-14-9 AMIODARONE 1951-25-3 ANILOPAM 53716-46-4 AMIPERONE 1580-71-8 ANIPAMIL 83200-10-6 AMIPHENAZOLE 490-55-1 ANIRACETAM 72432-10-1 AMIPIZONE 69635-63-8 ANIROLAC 66635-85-6 AMIPRILOSE 56824-20-5 ANISACRIL 5129-14-6 AMIQUINSIN 13425-92-8 ANISINDIONE
Load more

Recommended publications
  • Ep 2492268 A1
    (19) & (11) EP 2 492 268 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.08.2012 Bulletin 2012/35 C07D 407/10 (2006.01) A61K 31/405 (2006.01) (21) Application number: 12168896.4 (22) Date of filing: 20.07.2007 (84) Designated Contracting States: • Wynne, Graham Michael AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Abingdon, Oxfordshire OX14 4RY (GB) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Dorgan, Colin Richard SI SK TR Abingdon, Oxfordshire OX14 4RY (GB) Designated Extension States: • Johnson, Peter David AL BA HR MK RS Abingdon, oxfordshire OX14 4RY (GB) (30) Priority: 22.07.2006 GB 0614608 (74) Representative: Hollywood, Jane Constance 04.12.2006 GB 0624176 Kilburn & Strode LLP 20 Red Lion Street (62) Document number(s) of the earlier application(s) in London WC1R 4PJ (GB) accordance with Art. 76 EPC: 07766323.5 / 2 046 740 Remarks: This application was filed on 22-04-2012 as a (71) Applicant: Oxagen Limited divisional application to the application mentioned Oxfordshire OX14 4RY (GB) under INID code 62. (72) Inventors: • Armer, Richard Edward Abingdon, Oxfordshire OX14 4RY (GB) (54) Compounds having CRTH2 antagonist activity (57) Compounds of general formula (1) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically ac- ceptable salts, hydrates, solvates, complexes or prod- rugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, aller- gic rhinitis and atopic dermatitis. EP 2 492 268 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 492 268 A1 Description [0001] The present invention relates to compounds which are useful as pharmaceuticals, to methods for preparing these compounds, compositions containing them and their use in the treatment and prevention of allergic diseases such 5 as asthma, allergic rhinitis and atopic dermatitis and other inflammatory diseases mediated by prostaglandin D 2 (PGD2) or other agonists acting at the CRTH2 receptor on cells including eosinophils, basophils and Th2 lymphocytes.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Identificación Computacional De Nuevos Compuestos Líderes Con Actividad Analgésica
    IDENTIFICACIÓN COMPUTACIONAL DE NUEVOS COMPUESTOS LÍDERES CON ACTIVIDAD ANALGÉSICA Autor: Earmin Shangoo. Tutores: Dr. Yovani Marrero Ponce MSc. Arelys López Sacerio Lic. Gerardo Maikel Casañola Martín “Año 49 de la Revolución Cubana” Curso 2006-2007 PENSAMIENTO “For all flesh is as grass, and all the glory of man as the flower of grass. The grass withereth, and the flower thereof falleth away: But the word of the Lord endureth for ever.” 1 Peter1:24,25. “Todo carne es como hierba y toda la gloria del hombre como flor de la hierba; la hierba se seca y la flor se cae, mas la palabra del Señor permanece para siempre.” 1 Pedro 1:24,25. DEDICATORIA For all my friends and family, especially my daughter, Naarah Melani Nerissa Athanase and my husband, Jeremiah Wayn Athanase, with love and admiration. “I have fought a good fight, I have finished my course…” 2Tim 4:7. Con mucho cariño y admiración, a todas mis amigos y mi familia en particular a mi hija, Naarah Melani Nerissa Athanase y mi esposo, Jeremiah Wayn Athanase. “He peleada la buena batalla, he acabado la carrera…” 2Ti 4:7 AGRADECIMIENTOS For me it is an enormous pleasure to be able to express my sincere gratefulness to all those people that in one way or another has helped me to successfully culminate my studies and this work. I would especially like to thank God because without him I am nothing; to my family for their faith, support, love and patience; to my tutors especially Arelys for their attention, dedication and orientation during this work; to all the professors of the career that made possible with their patient, constant and opportune help my formation as a pharmaceutical professional; to my friends, in particular to Solange and Harun; to all thank you.
    [Show full text]
  • TARIF DES DOUANES - ANNEXE 99 - I
    TARIF DES DOUANES - ANNEXE 99 - i Chapitre 99 DISPOSITIONS DE CLASSIFICATION SPÉCIALE - COMMERCIALES Notes. 1. Les dispositions du présent Chapitre ne sont pas régies par la règle de spécificité de la Règle générale interprétative 3 a). 2. Les marchandises qui peuvent être classées dans les dispositions du Chapitre 99, sont classées dans le Chapitre 98 si elles peuvent également être classées dans ce chapitre. 3. Les marchandises peuvent être classées dans un numéro tarifaire du présent Chapitre et peuvent bénéficier des taux de droits de douane du tarif de la nation la plus favorisée ou du tarif de préférence prévus au présent Chapitre qui s’appliquent à ces marchandises selon le traitement tarifaire applicable selon le pays d’origine, mais ce classement est subordonné au classement préalable de celles-ci dans un numéro tarifaire des Chapitres 1 à 97 et à l’observation des conditions prévues par les textes d’application qui leurs sont applicables. 4. Les termes utilisés dans ce Chapitre et dans les Chapitres 1 à 97 s’entendent au sens de ces derniers Chapitres. Émis 1 janvier 2018 99 - 1 TARIF DES DOUANES - ANNEXE Numéro Unité Tarif de la Tarif de préférence SS Dénomination des marchandises tarifaire de mes. N.P.F. applicable 9901.00.00 Articles et matières devant servir à la fabrication ou à la réparation des En fr. TPAC, TPMD, TPG, produits suivants devant être utilisés dans la pêche commerciale ou TÉU, TM, TMÉU, TACI, dans la récolte commerciale de plantes aquatiques : TC, TCR, TI, TN, TSL, TP, TCOL, TJ, TPA, Appâts artificiels; TNH, TKR, TCUE, TUA : En fr.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Aryloxime Aryloximes Aryloxymes
    (19) TZZ___¥_T (11) EP 1 511 737 B1 (12) EUROPÄISCHE PATENTSCHRIFT (45) Veröffentlichungstag und Bekanntmachung des (51) Int Cl.: Hinweises auf die Patenterteilung: C07D 237/04 (2006.01) C07D 401/12 (2006.01) 17.02.2010 Patentblatt 2010/07 A61K 31/50 (2006.01) A61P 37/00 (2006.01) (21) Anmeldenummer: 03732395.3 (86) Internationale Anmeldenummer: PCT/EP2003/005173 (22) Anmeldetag: 16.05.2003 (87) Internationale Veröffentlichungsnummer: WO 2003/104205 (18.12.2003 Gazette 2003/51) (54) ARYLOXIME ARYLOXIMES ARYLOXYMES (84) Benannte Vertragsstaaten: • BEIER, Norbert AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 64354 Reinheim (DE) HU IE IT LI LU MC NL PT RO SE SI SK TR • SCHELLING, Pierre Benannte Erstreckungsstaaten: 64367 Mühltal (DE) LT LV • WOLF, Michael 64297 Darmstadt (DE) (30) Priorität: 10.06.2002 DE 10225574 (56) Entgegenhaltungen: (43) Veröffentlichungstag der Anmeldung: WO-A-98/06704 WO-A-99/65880 09.03.2005 Patentblatt 2005/10 Bemerkungen: (73) Patentinhaber: Merck Patent GmbH Die Akte enthält technische Angaben, die nach dem 64293 Darmstadt (DE) Eingang der Anmeldung eingereicht wurden und die nicht in dieser Patentschrift enthalten sind. (72) Erfinder: • EGGENWEILER, Hans-Michael 64291 Darmstadt (DE) Anmerkung: Innerhalb von neun Monaten nach Bekanntmachung des Hinweises auf die Erteilung des europäischen Patents im Europäischen Patentblatt kann jedermann nach Maßgabe der Ausführungsordnung beim Europäischen Patentamt gegen dieses Patent Einspruch einlegen. Der Einspruch gilt erst als eingelegt, wenn die Einspruchsgebühr entrichtet
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities
    77 A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities Hernán Pessoa-Mahana* 1 ; Ramiro Araya-Maturana1 , Claudio Saitz, B.1 and C. David Pessoa-Mahana2 1Departamento de Química Orgánica y Fisicoquímica. Facultad de Ciencias Químicas y Farmacéuticas. Universidad de Chile. Olivos 1007.Casilla 233. Santiago 1. Chile 2Departamento de Farmacia. Facultad de Química. Pontificia Universidad Católica de Chile. Vicuña Mackenna 4860-Casilla 306, Correo 22 Santiago-Chile Abstract: The present review discusses the synthetic strategies of new ligands exhibiting mainly 5-HT1A binding affinities. Specifically we focused our attention in the synthesis of compounds structurally related to arylpiperazine, 2-aminotetralin, and benzopyran derivatives. Keywords: serotonin, 5-HT1A ligands, arylpiperazines, aminotetralins, benzopyrans. INTRODUCTION During the last 15 years, seven distinct families of 5-HT receptors have been identified (5-HT1–5-HT7), and at least Depression is one of the most common illnesses, 15 subpopulations have been described for several of these affecting up to one-third of all people at the same time. [4,5]. The 5-HT1A receptors represent a major target for Depressive disorders encompass a variety of conditions neurobiological research and drug developments. A study on including two major forms of unipolar depression (i.e. major distribution of 5-HT1A receptors in the brains of various depression and dysthymia), adjustment disorders, animal species indicates that the highest densities are located subsyndromal depression (minor depression), seasonal in the hippocampus, septum, amygdale, and cortical limbic affective disorder (SAD), premenstrual dysphoric disorder areas. The 5-HT1A receptors located in the raphe nuclei are (PMDD), postpartum depression, atypical depression and known as somatodendritic autoreceptors.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]